TT 223

Drug Profile

TT 223

Alternative Names: G1 - Transition Therapeutics; TT-223

Latest Information Update: 27 Sep 2010

Price : $50

At a glance

  • Originator Transition Therapeutics
  • Class Antihyperglycaemics; Biguanides; Gastrointestinal hormones; Hormones; Neuropeptides; Peptide hormones
  • Mechanism of Action Gastrin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 17 Sep 2010 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (SC)
  • 03 Feb 2010 Safety and efficacy data from a phase II trial in Type-2 diabetes mellitus released by Transition Therapeutics
  • 10 Feb 2009 Transition Therapeutics completes enrolment in its phase II trial for Type 2 diabetes mellitus in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top